申红红,卢 玮,赵长青,张晓寒,王 晨

目的：探讨伴有髓样特征的浸润性癌中GSDMC和PD-L1的表达与临床病理特征及预后的相关性。方法：收集山西医科大学第二医院2015-2022年伴有髓样特征的浸润性癌标本57例，评估每例CD8+TIL的浸润密度，免疫组化检测GSDMC和PD-L1的表达。结果：57例IBC-NST中35例GSDMC阳性表达（61.4%），且GSDMC的表达与组织学分级、肿瘤坏死（、Ki67增殖指数（、PD-L1及CD8+TIL相关。17例PD-L1阳性表达（29.8%），PD-L1表达与脉管侵犯、肿瘤坏死及CD8+TIL相关。生存分析发现GSDMC阳性表达和CD8+TIL低密度浸润具有更短的无复发生存时间和无远处转移生存时间。结论：GSDMC可能与PD-L1相互作用，抑制CD8+TIL浸润，进而参与肿瘤免疫。

伴有髓样特征的浸润性乳腺癌；GSDMC；PD-L1；CD8+肿瘤浸润淋巴细胞；肿瘤免疫

[1] 杨文涛,步宏.第 5 版 WHO 乳腺肿瘤分类解读[J].中华病理学杂志,2020,49（5）:400-405. [2] 郭存存,李真真,翟振国,等.髓样型浸润性乳腺癌非特殊类型并腋窝淋巴结痣一例及文献复习[J].诊断病理学杂志,2021,28(11):946-949. [3] 夏琛,吴义启,王晖,等.乳腺髓样癌 9 例临床病理学观察[J].临床与实验病理学杂志,2016,32(5):576-578. [4] Hou J,Zhao R,Xia W,et al.PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosisl[J].Nat Cell Biol,2020,22(10):1264-1275. [5] Zhang Z,Zhang Y,Xia S,et al.Gasdermin E suppresses tumour growth by activating anti-tumour immunityl[J]. Nature, 2020, 579(7799): 415-420. [6] Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 triall[J]. Lancet Oncol,2020,21(1):44-59. [7] Varun Kumar,Jianjun Yu,Vernon Phan,et al.Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer.JCO Precis Oncol,2017,1:1-19. [8] Chen L, Jiang YZ, Wu SY, et al. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial[J]. Clin Cancer Res,2022,28(13):2807-2817. [9] Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014[J].Ann Onco,2015,26(2): 259-271. [10] Cheng Yan,Yandie Niu,Feng Li,et al.System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma[J].J Transl Med,2022,20:455. [11] Lotfinejad P, Asghari Jafarabadi M, Abdoli Shadbad M,et al. Prognostic role and clinical significance of tumor-infiltrating lymphocyte(TIL) and programmed death ligand 1 (PD-L1) expression in triple-negative breast cancer (TNBC): a systematic review and Meta-analysis study[J].Diagnostics (Basel)，2020，10(9):704.

点击下载PDF